Impact News +++ CACI: Military Appreciation Profile: Denyse S. Gordon-Watts Helps Veterans Thrive After Military Service (Accesswire) +++ CACI Aktie +3,14%

CLINUVEL Aktie

>CLINUVEL Aktienkurs

5.892 EUR -0.7% (TradegateBSX)

Ask: 5.892 EUR / 1208 Stück

Bid: 5.802 EUR / 1229 Stück

Tagesumsatz: 2186 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

CLINUVEL Aktie über LYNX handeln

Intraday

1 Jahr

>CLINUVEL Performance

1 Woche: +4,2%

1 Monat: +7,5%

3 Monate: -11,9%

6 Monate: -1,0%

1 Jahr: -6,8%

laufendes Jahr: -15,4%

>CLINUVEL Aktie

Name:

CLINUVEL PHARMACEUTICALS

Land:

Australien

Sektor:

Gesundheit

ISIN/ Wkn:

AU000000CUV3 / A0JEGY

Symbol/ Ticker:

UR9 (Frankfurt)

Kürzel:

FRA:UR9, ETR:UR9, UR9:GR

Index:

Webseite:

https://www.clinuvel.com

Profil:

Clinuvel Pharmaceuticals Ltd is a global specialty biotechnology company dedicated to the development and commercialization of innovative treatments for rare and severe medical conditions. The company focuses particularly on disorders related to ligh..
>Volltext..

Marktkapitalisierung:

284.03 Mio. EUR

Unternehmenswert:

151.73 Mio. EUR

Umsatz:

54.83 Mio. EUR

EBITDA:

22.21 Mio. EUR

Nettogewinn:

18.53 Mio. EUR

Gewinn je Aktie:

0.37 EUR

Schulden:

0.18 Mio. EUR

Liquide Mittel:

20.57 Mio. EUR

Operativer Cashflow:

23.04 Mio. EUR

Bargeldquote:

13.05

Umsatzwachstum:

-0.02%

Gewinnwachstum:

-20.23%

Dividende je Aktie:

0.03 EUR

Dividendenrendite:

0.55%

Dividendenschätzung:

0.54%

Div. Historie:

04.09.25 - 0.027875€
05.09.24 - 0.027875€

>weitere anzeigen...

Insiderhandel:

Suchwörter:

CLINUVEL

Letzte Datenerhebung:

06.05.26

>CLINUVEL Kennzahlen

Aktien/ Unternehmen:

Aktien: 50.41 Mio. St.

Frei handelbar: 83.24%

Leerverk. Aktien: -

Rückkaufquote: -

Mitarbeiter: -

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 161.3%

Bewertung:

KGV: 15.35

KGV lG: 12.66

KUV: 4.54

KBV: 1.99

PEG-Ratio: -

EV/EBITDA: 6.83

Rentabilität:

Bruttomarge: 63.71%

Gewinnmarge: 33.79%

Operative Marge: 39.39%

Managementeffizenz:

Gesamtkaprendite: 12.86%

Eigenkaprendite: 13.96%

>CLINUVEL Peer Group

Gesundheit, Stoffwechselerkrankungen (Diabetes/ Adipositas), Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten

>CLINUVEL Chart & Kurs - Tradegate

>CLINUVEL News

24.04.26 - 07:51	CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study (GlobeNewswire EN)
	“Totality of evidence” approach to evaluate SCENESSE® “Totality of evidence” approach to evaluate SCENESSE®...

15.04.26 - 08:21	CLINUVEL: advancing peptides for photomedicine and vitiligo care at AAD 2026 (GlobeNewswire EN)
	AAD 2026 reinforces CLINUVEL's expertise in dermatology AAD 2026 reinforces CLINUVEL's expertise in dermatology...

27.03.26 - 03:48	Clinuvel Showcases AI-Powered Vitiligo Assessment Tool at AAD Conference (Small Caps)
	Clinuvel unveils AI Vitiligo Visual Algorithm at AAD 2026, linking VVA to CUV107 Phase III; H1 FY26 revenue +4%, PAT -26% on higher costs....

27.03.26 - 03:12	Why 4DMedical, Clinuvel, Life360, and Silex shares are pushing higher today (Fool)
	These shares are having a good finish to the week. But why? The post Why 4DMedical, Clinuvel, Life360, and Silex shares are pushing higher today appeared first on The Motley Fool Australia....

26.02.26 - 18:12	Clinuvel Pharmaceuticals reports 2H results (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

26.02.26 - 12:24	Clinuvel meldet Rekordumsatz, doch Kostenanstieg belastet Aktie (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

08.12.25 - 04:00	Why Artrya, Clinuvel, Imugene, and Pilbara Minerals shares are storming higher today (Fool)
	These shares are starting the week in a positive fashion. But why? The post Why Artrya, Clinuvel, Imugene, and Pilbara Minerals shares are storming higher today appeared first on The Motley Fool Australia....

08.12.25 - 03:39	CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies (GlobeNewswire EN)
	EXECUTIVE SUMMARY...

29.09.25 - 05:00	CLINUVEL to advance novel pharmaceutical formulations in preclinical program (GlobeNewswire EN)
	Next generation sustained-release formulations for a variety of peptides Next generation sustained-release formulations for a variety of peptides...

23.09.25 - 04:12	Why Clinuvel, DroneShield, Nuix, and Telix shares are storming higher today (Fool)
	These shares are climbing more than most today. But why? The post Why Clinuvel, DroneShield, Nuix, and Telix shares are storming higher today appeared first on The Motley Fool Australia....

19.09.25 - 06:00	Why Clinuvel, CSL, Pro Medicus, and Zip shares are racing higher today (Fool)
	These shares are ending the week with a bang. But why? The post Why Clinuvel, CSL, Pro Medicus, and Zip shares are racing higher today appeared first on The Motley Fool Australia....

02.09.25 - 23:51	XFRA: DIVIDEND/INTEREST INFORMATION - 04.09.2025 - AU000000CUV3 (XETRA)
	Das Instrument UR9 AU000000CUV3 CLINUVEL PHARMACEUTICALS EQUITY wird cum Dividende/Zinsen gehandelt am 03.09.2025 und ex Dividende/Zinsen am 04.09.2025 The instrument UR9 AU000000CUV3 CLINUVEL PHARMACEUTICALS EQUITY has its pre-dividend/interest day on 03.09.2025 and its ex-dividend/interest day on 04.09.2025...

28.08.25 - 15:12	Clinuvel Pharmaceuticals reports FY results (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

22.08.25 - 09:48	CLINUVEL preparing upgrade of ADR program to Level II, Nasdaq uplist (GlobeNewswire EN)
	Executive summary...

22.08.25 - 06:48	Why Clinuvel, Cuscal, EOS, and Zip shares are storming higher today (Fool)
	These shares are ending the week with a bang. But why? The post Why Clinuvel, Cuscal, EOS, and Zip shares are storming higher today appeared first on The Motley Fool Australia....

23.06.25 - 12:45	Corporate News: Parmantier & Cie. GmbH (EQS)
	CLINUVEL Update: CEO Comeback & US Expansion Drive: Vitiligo-Zulassung und M&A als Wachstumstreiber in Nordamerika...

13.06.25 - 03:30	Clinuvel shares dip, even as CEO comes back from temp leave (Market Herald)
	After Clinuvel's (ASX:CUV) CEO, Dr. Philippe Wolgen, took time off back in…...

26.05.25 - 09:48	Clinuvel: „Weglegeaktie“, die drei Generationen begeistern wird? (GoingPublic)
	Bildnachweis: musa – stock.adobe.com, stock3.com. Das Spezialpharmaunternehmen Clinuvel ist gut ins Geschäftsjahr 2025 gestartet und treibt seine Entwicklung aggressiv voran. So konnten im ersten Halbjahr 2025 (abgelaufenes Geschäftsjahr endete am […] Der Beitrag Clinuvel: „Weglegeaktie“, die drei Generationen begeistern wird? erschien zuerst auf GoingPublic.de....

07.05.25 - 06:12	CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105 (GlobeNewswire EN)
	CLINUVEL has met its recruitment target in its phase III trial (CUV105) of SCENESSE® (afamelanotide 16mg) in vitiligo, with more than 200 patients enrolled...

07.05.25 - 03:36

Clinuvel Pharmaceuticals reaches patient recruitment milestone ahead of Phase III Scenesse vitiligo trial (Small Caps)

Clinuvel Pharmaceuticals (ASX: CUV) has recruited more than 200 patients for a Phase III trial (CUV105) of its breakthrough Scenesse (afamelanotide 16mg) repigmentation therapy to treat vitiligo. The company is conducting the randomised 20-week trial at 37 sites across North America, Africa and Europe, with 57% of patients enrolled in the US. The last patient […] The post Clinuvel Pharmaceuticals reaches patient recruitment milestone ahead of Phase III Scenesse vitiligo trial appeared first on Small Caps....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Die fleißige Biene hat keine Zeit für Kummer. - William Blake

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram